How do you decide between systemic antiangiogenic therapies for HHT?

Pomalidomide was just recently published in NEJM (Al-Samkari et al., PMID 39292928) showing efficacy in improving epistaxis in patients with HHT. It has an advantage as it is an oral agent versus bevacizumab being an IV infusion. Bevacizumab, however, has previously shown efficacy in smaller studies for its effect on liver and GI AVMs in addition to epistaxis. Therefore, would need to consider total organ involvement when considering the selection of medication agents.